AstraZeneca stock value falls by nearly £14bn after cancer drug trial results

Shares close down 8% on concerns that new lung cancer drug may not be as successful as hoped

Nearly 14bn has been wiped off the stock market value of AstraZeneca over concerns that a new lung cancer drug may not be as successful as had been hoped.

Shares in the Anglo-Swedish pharmaceutical company closed down 8% on Monday after it published the first results from its phase 3 trial for datopotamab deruxtecan, making it the biggest faller among FTSE 100 companies.